Estrella Immunopharma Financials
This page shows Estrella Immunopharma (ESLAW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Estrella Immunopharma passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Estrella Immunopharma generates $2.20 in operating cash flow (-$16.1M OCF vs -$7.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Estrella Immunopharma reported -$7.3M in net income in fiscal year 2024. This represents an increase of 34.2% from the prior year.
Estrella Immunopharma earned $-0.27 per diluted share (EPS) in fiscal year 2024. This represents an increase of 99.3% from the prior year.
Estrella Immunopharma held $4.2M in cash against $0 in long-term debt as of fiscal year 2024.
Estrella Immunopharma had 37M shares outstanding in fiscal year 2024. This represents an increase of 1588.4% from the prior year.
Estrella Immunopharma invested $4.1M in research and development in fiscal year 2024. This represents a decrease of 60.7% from the prior year.
Estrella Immunopharma spent $354K on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding.
ESLAW Income Statement
| Metric | Q3'25 | Q3'24 | Q3'23 | Q1'23 | Q2'23 | Q3'22 | Q2'22 | Q4'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $4.2M+46.9% | $2.8M+3645.1% | $75K-84.4% | $483K | N/A | $2.6M | N/A | N/A |
| SG&A Expenses | $649K+17.8% | $551K-41.7% | $945K-31.9% | $1.4M | N/A | $148K | N/A | N/A |
| Operating Income | -$4.8M-42.2% | -$3.4M-230.9% | -$1.0M+45.4% | -$1.9M-1005.3% | -$169K+93.9% | -$2.8M-550.4% | -$424K | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $850-47.7% | $2K-91.7% | $19K | N/A | $21K | $0 | $0 | N/A |
| Net Income | -$4.8M-42.2% | -$3.4M-230.9% | -$1.0M+45.4% | -$1.9M-2361.1% | -$76K+97.2% | -$2.8M-666.5% | -$360K | N/A |
| EPS (Diluted) | $-0.13-44.4% | $-0.09-200.0% | $-0.03+98.3% | $-1.78 | N/A | $-16.33 | $-0.06 | N/A |
ESLAW Balance Sheet
| Metric | Q3'25 | Q3'24 | Q3'23 | Q1'23 | Q2'23 | Q3'22 | Q2'22 | Q4'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.5M+12.2% | $3.1M-66.8% | $9.4M-65.5% | $27.3M+803.1% | $3.0M-68.9% | $9.7M-78.6% | $45.4M-0.9% | $45.8M |
| Current Assets | $2.0M+23.3% | $1.6M-82.6% | $9.4M | N/A | $2.8M+5149.6% | $52K-59.3% | $129K-79.1% | $616K |
| Cash & Equivalents | $1.6M+77.4% | $917K-89.9% | $9.0M-59.1% | $22.1M+793.0% | $2.5M+5976.0% | $41K-53.8% | $88K-81.6% | $479K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | $273K | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $13.4M+345.8% | $3.0M+651.6% | $399K-97.7% | $17.3M+17.0% | $14.8M-8.8% | $16.2M-65.1% | $46.4M-0.8% | $46.8M |
| Current Liabilities | $13.4M+345.8% | $3.0M+651.6% | $399K-97.7% | $17.3M+77.1% | $9.8M+809.4% | $1.1M+593.9% | $155K+111.4% | $73K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$9.8M-6943.6% | $144K-98.4% | $9.0M-10.1% | $10.1M+185.7% | -$11.7M-81.3% | -$6.5M-522.8% | -$1.0M-3.3% | -$1.0M |
| Retained Earnings | -$36.4M-52.0% | -$23.9M-58.7% | -$15.1M-7.3% | -$14.1M-15.3% | -$12.2M-440.3% | -$2.3M-49.7% | -$1.5M-49.8% | -$1.0M |
ESLAW Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q3'23 | Q1'23 | Q2'23 | Q3'22 | Q2'22 | Q4'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$727K+18.8% | -$896K+92.0% | -$11.3M-3994.2% | -$275K-536.4% | -$43K+69.1% | -$140K+40.0% | -$233K+20.4% | -$293K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | $0-100.0% | $5.1M+4617.4% | -$112K+17.8% | -$137K | N/A | N/A | $0 |
| Financing Cash Flow | $1.0M+6601.6% | $15K+100.2% | -$6.9M-134.4% | $20.0M+10100.0% | $197K+100.5% | -$36.1M | N/A | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $0-100.0% | $150K | N/A | N/A | N/A | N/A | N/A | N/A |
ESLAW Financial Ratios
| Metric | Q3'25 | Q3'24 | Q3'23 | Q1'23 | Q2'23 | Q3'22 | Q2'22 | Q4'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -136.3%-45.9pp | -90.4%-79.6pp | -10.8%-4.0pp | -6.8%-4.3pp | -2.5%+25.8pp | -28.3%-27.6pp | -0.8% | N/A |
| Current Ratio | 0.15-0.4 | 0.55-23.1 | 23.69 | N/A | 0.28+0.2 | 0.05-0.8 | 0.83-7.6 | 8.42 |
| Debt-to-Equity | -1.36-22.2 | 20.85+20.8 | 0.04-1.7 | 1.72+3.0 | -1.26+1.2 | -2.50+42.1 | -44.65+1.9 | -46.52 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Estrella Immunopharma profitable?
No, Estrella Immunopharma (ESLAW) reported a net income of -$7.3M in fiscal year 2024.
What is Estrella Immunopharma's earnings per share (EPS)?
Estrella Immunopharma (ESLAW) reported diluted earnings per share of $-0.27 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Estrella Immunopharma's operating cash flow?
Estrella Immunopharma (ESLAW) generated -$16.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Estrella Immunopharma's total assets?
Estrella Immunopharma (ESLAW) had $4.5M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Estrella Immunopharma spend on research and development?
Estrella Immunopharma (ESLAW) invested $4.1M in research and development during fiscal year 2024.
Does Estrella Immunopharma buy back shares?
Yes, Estrella Immunopharma (ESLAW) spent $354K on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.
How many shares does Estrella Immunopharma have outstanding?
Estrella Immunopharma (ESLAW) had 37M shares outstanding as of fiscal year 2024.
What is Estrella Immunopharma's current ratio?
Estrella Immunopharma (ESLAW) had a current ratio of 24.65 as of fiscal year 2024, which is generally considered healthy.
What is Estrella Immunopharma's debt-to-equity ratio?
Estrella Immunopharma (ESLAW) had a debt-to-equity ratio of 0.04 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Estrella Immunopharma's return on assets (ROA)?
Estrella Immunopharma (ESLAW) had a return on assets of -164.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Estrella Immunopharma's cash runway?
Based on fiscal year 2024 data, Estrella Immunopharma (ESLAW) had $4.2M in cash against an annual operating cash burn of $16.1M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Estrella Immunopharma's Piotroski F-Score?
Estrella Immunopharma (ESLAW) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Estrella Immunopharma's earnings high quality?
Estrella Immunopharma (ESLAW) has an earnings quality ratio of 2.20x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.